We are live on
!
Find out more
HP
HealthInvest Partners Portfolio holdings
AUM
$372M
1-Year Est. Return
59.89%
This Fund
S&P 500
This Quarter
Est. Return
-0.04%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$310M
AUM Growth
-$3.76M
(-1.2%)
Cap. Flow
+$165M
Cap. Flow
% of AUM
53.25%
Top 10 Holdings %
Top 10 Hldgs %
45.45%
Holding
43
New
4
Increased
13
Reduced
15
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$53.2M |
| 2 |
DexCom
DXCM
|
+$37.9M |
| 3 |
Intuitive Surgical
ISRG
|
+$24.6M |
| 4 |
Johnson & Johnson
JNJ
|
+$21.5M |
| 5 |
Cardinal Health
CAH
|
+$18.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$18.7M |
| 2 |
CVS Health
CVS
|
+$6.37M |
| 3 |
Boston Scientific
BSX
|
+$5.46M |
| 4 |
UFP Technologies
UFPT
|
+$5.1M |
| 5 |
Ionis Pharmaceuticals
IONS
|
+$5.09M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
NewAmsterdam Pharma
NAMS
$3.3B
| $5.51M | 1.78% |
94,796
-102,240
| -52% | -$3.33M |
|
27
Celcuity
CELC
$4.3B
| $5.14M | 1.66% |
141,296
+99,465
| +238% | +$10.8M |
|
|
ABVX
28
Abivax
ABVX
$11.1B
| $4.78M | 1.54% |
31,590
| – | – |
|
|
29
Cardinal Health
CAH
$55.9B
| $4.77M | 1.54% |
108,682
+85,212
| +363% | +$18.4M |
|
30
IDEAYA Biosciences
IDYA
$3.55B
| $4.01M | 1.3% |
31,133
-66,305
| -68% | -$2.22M |
|
31
Tango Therapeutics
TNGX
$4.44B
| $3.63M | 1.17% |
+29,915
| New | +$416K |
|
32
Spyre Therapeutics
SYRE
$9.06B
| $3.49M | 1.13% |
+62,735
| New | +$2.37M |
|
33
Disc Medicine
IRON
$3.12B
| $3.19M | 1.03% |
107,255
+59,288
| +124% | +$4.11M |
|
34
Compass Therapeutics
CMPX
$396M
| $3.05M | 0.99% |
41,831
-542,501
| -93% | -$3.13M |
|
35
UnitedHealth
UNH
$361B
| $2.77M | 0.9% |
14,636
| – | – |
|
|
36
DexCom
DXCM
$33.8B
| $2.64M | 0.85% |
584,332
+544,610
| +1,371% | +$37.9M |
|
|
BCAX
37
Bicara Therapeutics
BCAX
$1.56B
| $2.32M | 0.75% |
1,169,634
+1,058,271
| +950% | +$18.2M |
|
|
SLNO
38
DELISTED
Soleno Therapeutics
SLNO
| $2.21M | 0.71% |
90,184
+27,449
| +44% | +$1.08M |
|
39
Pyxis Oncology
PYXS
$179M
| $1.62M | 0.52% |
197,036
-420,209
| -68% | -$633K |
|
|
ACLX
40
DELISTED
Arcellx
ACLX
| – | – |
-41,717
| Closed | -$2.72M |
|
|
AUTL
41
Autolus Therapeutics
AUTL
$620M
| – | – |
-1,169,634
| Closed | -$2.33M |
|
42
Corbus Pharmaceuticals
CRBP
$184M
| – | – |
-107,255
| Closed | -$873K |
|
|
43
UFP Technologies
UFPT
$2.49B
| – | – |
-22,986
| Closed | -$5.1M |
|
Similar funds
KP
TCM
SAAM
PC
GIP
PC
DPCM
OCMH
HealthInvest Partners's Q1 2026 Portfolio in Review
As of Q1 2026, HealthInvest Partners held 43 positions worth $310M, down 1.2% from $313M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
HealthInvest Partners deployed $165M of net new capital in Q1 2026, opening 4 new positions and adding to 13 existing holdings. Its largest new stake was Johnson & Johnson: 92,377 shares worth $11.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Merck, an estimated $18.7M trimmed.
- HealthInvest Partners's largest Q1 2026 buy was Johnson & Johnson: 92,377 shares worth $11.9M.
- HealthInvest Partners added most to Revolution Medicines in Q1 2026, an estimated $53.2M increase.
- HealthInvest Partners's biggest Q1 2026 reduction was Merck, cutting an estimated $18.7M.
- HealthInvest Partners fully exited UFP Technologies in Q1 2026, selling an estimated $5.1M.
- HealthInvest Partners's ten largest holdings make up 45% of its $310M portfolio in Q1 2026.
- HealthInvest Partners opened 4 new positions and closed 4 in Q1 2026.
- HealthInvest Partners's portfolio value fell 1.2% quarter-over-quarter to $310M.
Based on HealthInvest Partners's 13F filing for Q1 2026, filed 11 May 2026.